Dasatinib is a kind of grey-white to yellow solid powder. CAS No.: 302962-29-8, molecular formula: c22h26cln7o2s, molecular weight: 488.00600. Dasatinib, originally researched by Bristol Myers Squibb, was approved to be listed by FDA on June 28, 2006, under the trade name of Sprycel.
Dasatinib is a multi-target receptor tyrosine kinase inhibitor and a dual inhibitor of BCR-ABL and Src family kinases. In 2006, dasatinib was approved by the FDA for the treatment of adult patients with chronic myeloid leukaemia (CML) who were resistant or intolerable to imatinib mesylate.
In 2009, dasatinib was approved for the treatment of various stages of chronic myeloid leukaemia (CML), chronic myeloid leukaemia (CML) resistant or intolerable to therapeutic regimens including imatinib mesylate, and Philadelphia chromosome-positive (Ph + all) acute lymphoblastic leukaemia (Ph + all).
In 2010, dasatinib CAS 302962-29-8 was approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CP-CML).
However, in addition to leukaemia, dasatinib has great potential to treat other tumours.
It can target a protein called bcr-abl, which can accelerate the proliferation of tumour cells. Bcr-Abl protein is very similar to Fyn protein, which is found in other cancers, including breast cancer, brain cancer, pancreatic cancer, skin cancer, head and neck cancer. Fyn is associated with intercellular adhesion and cell migration. At present, a number of clinical trials are in progress to test the therapeutic effect of dasatinib on melanoma, prostate cancer, pancreatic cancer, endometrial cancer, gastrointestinal stromal cancer, ovarian cancer, etc.
Dasatinib CAS 302962-29-8 also showed the potential to delay the development of DMD. In addition, the new study found that for some imatinib-resistant gastrointestinal stromal tumour patients, dasatinib may be effective and worthy of expectation.